Developing a Method for Quantifying Meropenem in Children-Volumetric Adsorptive Microsampling Versus Plasma Sampling.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
08
11
2022
accepted:
12
03
2023
medline:
15
9
2023
pubmed:
18
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
Meropenem is a carbapenem antibiotic often used in pediatric intensive care units due to its broad spectrum of activity. Therapeutic drug monitoring (TDM) is a useful tool to increase the effectiveness of meropenem by adjusting the dose based on plasma levels; however, the relatively large sample volume required for TDM can limit its use in children. Therefore, this study aimed to determine meropenem concentrations and consequently perform TDM effectively using the smallest possible sample volume. Volumetric absorptive microsampling (VAMS) is a sampling technology developed to collect a small, precise volume of blood. For the applicability of VAMS in TDM, plasma concentrations must be reliably calculated from whole blood (WB) collected by VAMS. VAMS technology using 10 µL of WB was evaluated and compared with EDTA-plasma sampling. High-performance liquid chromatography with UV detection was applied to quantify meropenem in VAMS and plasma samples after the removal of proteins by precipitation. Ertapenem was used as the internal standard. Samples were collected simultaneously from critically ill children receiving meropenem using VAMS and traditional sampling. It was found that no consistent factor could be determined to calculate meropenem plasma concentrations from the WB, indicating that VAMS was not reliable in the TDM of meropenem. Therefore, to reduce the required sample amount in pediatric patients, a method for quantifying meropenem from 50 µL of plasma with a lower limit of quantification of 1 mg/L was developed and successfully validated. A simple, reliable, and low-cost method was established using high-performance liquid chromatography-UV to determine the concentration of meropenem in 50 µL of plasma. VAMS using WB does not seem to be suitable for TDM of meropenem.
Sections du résumé
BACKGROUND
Meropenem is a carbapenem antibiotic often used in pediatric intensive care units due to its broad spectrum of activity. Therapeutic drug monitoring (TDM) is a useful tool to increase the effectiveness of meropenem by adjusting the dose based on plasma levels; however, the relatively large sample volume required for TDM can limit its use in children. Therefore, this study aimed to determine meropenem concentrations and consequently perform TDM effectively using the smallest possible sample volume. Volumetric absorptive microsampling (VAMS) is a sampling technology developed to collect a small, precise volume of blood. For the applicability of VAMS in TDM, plasma concentrations must be reliably calculated from whole blood (WB) collected by VAMS.
METHODS
VAMS technology using 10 µL of WB was evaluated and compared with EDTA-plasma sampling. High-performance liquid chromatography with UV detection was applied to quantify meropenem in VAMS and plasma samples after the removal of proteins by precipitation. Ertapenem was used as the internal standard. Samples were collected simultaneously from critically ill children receiving meropenem using VAMS and traditional sampling.
RESULTS
It was found that no consistent factor could be determined to calculate meropenem plasma concentrations from the WB, indicating that VAMS was not reliable in the TDM of meropenem. Therefore, to reduce the required sample amount in pediatric patients, a method for quantifying meropenem from 50 µL of plasma with a lower limit of quantification of 1 mg/L was developed and successfully validated.
CONCLUSIONS
A simple, reliable, and low-cost method was established using high-performance liquid chromatography-UV to determine the concentration of meropenem in 50 µL of plasma. VAMS using WB does not seem to be suitable for TDM of meropenem.
Identifiants
pubmed: 37199434
doi: 10.1097/FTD.0000000000001105
pii: 00007691-990000000-00115
doi:
Substances chimiques
Meropenem
FV9J3JU8B1
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
623-630Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Baldwin C, Lyseng-Williamson K, Keam S. Meropenem. Drugs. 2008;68:803–838.
Steffens N, Zimmermann E, Nichelle S, et al. Meropenem use and therapeutic drug monitoring in clinical practice: a literature review. J Clin Pharm Ther. 2021;46:610–621.
Scharf C, Paal M, Schroeder I, et al. Therapeutic drug monitoring of meropenem and piperacillin in critical illness—experience and recommendations from one year in routine clinical practice. Antibiotics. 2020;9:131..
de With K, Allerberger F, Amann S, et al. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection. 2016;44:395–439.
Hagel S, Bach F, Brenner T, et al. Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med. 2022;48:311–321.
Roberts A, Paul K, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58:1072–1083. .
Roth T, Fiedler S, Mihai S, et al. Determination of meropenem levels in human serum by high‐performance liquid chromatography with ultraviolet detection. Biomed Chromatogr. 2017;31:e3880.
Martens-Lobenhoffer J, Monastyrski D, Tröger U, et al. Stability of meropenem in plasma versus dried blood spots (DBS). J Pharm Biomed Anal. 2019;170:279–284.
Carlier M, Stove V, Wallis S, et al. Assays for therapeutic drug monitoring of β-lactam antibiotics: a structured review. Int J Antimicrob Agents. 2015;46:367–375.
Briscoe S, McWhinney B, Lipman J, et al. A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B. 2012;907:178–184.
Casals G, Hernandez C, Hidalgo S, et al. Development and validation of a UHPLC diode array detector method for meropenem quantification in human plasma. Clin Biochem. 2014;47:223–227.
Dailly E, Bouquie R, Deslandes G, et al. A liquid chromatography assay for a quantification of doripenem, ertapenem, imipenem, meropenem concentrations in human plasma: application to a clinical pharmacokinetic study. J Chromatogr B. 2011;879:1137–1142.
Elkhaili H, Niedergang S, Pompei D, et al. High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B: Biomed Sci Appl. 1996;686:19–26.
McWhinney B, Wallis S, Hillister T, et al. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B. 2010;878:2039–2043.
Verdier M, Tribut O, Tattevin P, et al. Simultaneous determination of 12 β-lactam antibiotics in human plasma by high-performance liquid chromatography with UV detection: application to therapeutic drug monitoring. Antimicrob Agents Chemother. 2011;55:4873–4879.
Wolff F, Deprez G, Seyler L, et al. Rapid quantification of six beta-lactams to optimize dosage regimens in severely septic patients. Talanta. 2013;103:153–160.
Ahsman M, Wildschut E, Tibboel D, et al. Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. Antimicrob Agents Chemother. 2009;53:75–80.
Rigo-Bonnin R, Juvany-Roig R, Leiva-Badosa E, et al. Measurement of meropenem concentration in different human biological fluids by ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2014;406:4997–5007.
Carlier M, Stove V, De Waele J, et al. Ultrafast quantification of β-lactam antibiotics in human plasma using UPLC–MS/MS. J Chromatogr B. 2015;978–979:89–94.
Zander J, Maier B, Suhr A, et al. Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation. Clin Chem Lab Med (CCLM). 2015;53:781–791.
Martens-Lobenhoffer J, Bode-Böger S. Quantification of meropenem in human plasma by HILIC—tandem mass spectrometry. J Chromatogr B. 2017;1046:13–17.
Antunes M, Charão M, Linden R. Dried blood spots analysis with mass spectrometry: potentials and pitfalls in therapeutic drug monitoring. Clin Biochem. 2016;49:1035–1046.
Evans C, Arnold M, Bryan P, et al. Implementing dried blood spot sampling for clinical pharmacokinetic determinations: considerations from the IQ Consortium Microsampling Working Group. AAPS J. 2015;17:292–300.
Barco S, Castagnola E, Moscatelli A, et al. Volumetric adsorptive microsampling-liquid chromatography tandem mass spectrometry assay for the simultaneous quantification of four antibiotics in human blood: method development, validation and comparison with dried blood spot. J Pharm Biomed Anal. 2017;145:704–710. .
Spooner N, Denniff P, Michielsen L, et al. A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated blood hematocrit. Bioanalysis. 2015;7:653–659.
Kok M, Fillet M. Volumetric absorptive microsampling: current advances and applications. J Pharm Biomed Anal. 2018;147:288–296.
Denniff P, Spooner N. Volumetric absorptive microsampling: a dried sample collection technique for quantitative bioanalysis. Anal Chem. 2014;86:8489–8495.
European Medicines Agency. Guideline on Bioanalytical Method Validation; 2015. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf . Accessed September 11 2021.
U.S. Department of Health and Human Services—Food and Drug Administration (FDA), Bioanalytical Method Validation—Guidance for Industry. 2018. Available at: https://www.fda.gov/media/70858/download . Accessed September 21, 2021.
Andriguetti N, Lisboa L, Hahn S, et al. Simultaneous determination of vancomycin and creatinine in plasma applied to volumetric absorptive microsampling devices using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2019;165:315–324. .
Zou L, Meng F, Hu L, et al. A novel reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of imipenem and meropenem in human plasma and its application in TDM. J Pharm Biomed Anal. 2019;169:142–150. .
Roth T, Weber L, Niestroj M, et al. Simultaneous determination of six antibiotics in human serum by high‐performance liquid chromatography with UV detection. Biomed Chromatogr BMC. 2021;35:e5010.